Market Cap
$1.9B
BLFS
BIOLIFE SOLUTIONS INC
$37.30 ▲ +1.41%
Prev close $36.78Market cap$1.9B
ConsensusHold
12-mo target$31.29 (-16.1%)
▲ Neutral
Analyst conviction 5/10
Insider Selling Cluster (6 insiders)High Impact Filing (7/10)14 New Institutional Positions10 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on BLFS right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Hold (47%)
Inst. Holders
50 funds
Inst. Value
$828.8M
Inst. Activity
14 buys / 10 sells
Insider Activity
$0.00 buy / $30.2M sell
Insider Net $
-$30.2M
SEC Reports
5
Price chart 30d +5.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 18, 2026 Insider
Berard Todd surrendered for taxes 470 shares
Chief Marketing Officer @ $36.69 ($17.2K)
Sep 18, 2026 Insider
Werner Sean surrendered for taxes 421 shares
Chief Technology Officer @ $36.69 ($15.4K)
Sep 18, 2026 Insider
Sep 4, 2026 SEC Mathew Aby J. surrendered for taxes 564 shares
EVP & Chief Scientific Officer @ $36.69 ($20.7K)
BioLife Solutions (BLFS) is seeking stockholder approval for its acquisition by Repligen Corporation (RGEN) in a cash-an
DEFM14A — Impact 7/10
Aug 6, 2026 earnings_calendar
BLFS Q2 2026 Earnings Scheduled — 2026-08-06
Jun 30, 2026 Inst.
FMR LLC — TRIM
993,106 shares ($28.0M)
Jun 30, 2026 Inst.
Jun 3, 2026 SEC UBS Group AG — DOUBLED
832,143 shares ($23.5M)
BioLife Solutions filed an 8-K furnishing an investor presentation for the Jefferies Global Healthcare Conference. The p
8-K — Impact 3/10
Analyst ratings buy % -50.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
47% rate it Buy or better · 15 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 10, 2026 | Benchmark | DOWNGRADE | Hold | 54% |
| Jul 27, 2026 | Stephens & Co. | DOWNGRADE | Equal-Weight | 54% |
| Jul 23, 2026 | Jefferies | DOWNGRADE | Hold | 53% |
| Jul 23, 2026 | TD Cowen | DOWNGRADE | Hold | 56% |
| Jul 22, 2026 | Lake Street | DOWNGRADE | Hold | 45% |
| Jul 22, 2026 | HC Wainwright & Co. | DOWNGRADE | Neutral | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 5 | 8 | 0 | 0 | 47% | |
| Aug 1, 2026 | 2 | 5 | 8 | 0 | 0 | 47% | |
| Jul 1, 2026 | 4 | 10 | 1 | 0 | 0 | 93% | |
| Jun 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% |
Price targets
Where 7 covering analysts think BLFS trades over the next 12 months.
$31.29 -16.1% upside Strong Sell
Current$37.30 Low$31.00 Median$31.00 High$33.00 7 analysts
$31.00$33.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 1 bullish, 1 bearish, 0 mixed, 3 neutral · avg impact 4.2/10.
BULLISHDEFM14A7/10
BioLife Solutions (BLFS) is seeking stockholder approval for its acquisition by Repligen Corporation
Sep 4, 2026
NEUTRAL8-K3/10
BioLife Solutions filed an 8-K furnishing an investor presentation for the Jefferies Global Healthca
Jun 3, 2026
NEUTRAL10-K/A2/10
BioLife Solutions filed Amendment No. 1 to its 2025 10-K solely to add Part III items (directors, ex
Apr 28, 2026
BEARISHCLUSTER6/10
Multiple C-suite executives at BioLife Solutions sold shares in a coordinated cluster over the past
Mar 9, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 6, 2026
earnings_calendar
BLFS Q2 2026 Earnings Scheduled — 2026-08-06
Jul 31, 2026
short_interest_report
Short Interest: BLFS up 59% to 4.5M shares
Settlement 2026-07-31 | Days to cover: 2.06 | ≈9.29% of shares outstanding (est.)
Jul 24, 2026
short_volume
Short Volume: BLFS — 60.3% short (0.9M / 1.6M)
Short: 946,886 | Exempt: 198 | TRF Vol: 1,569,258 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)
Jul 23, 2026
short_volume
Short Volume: BLFS — 61.0% short (1.3M / 2.2M)
Short: 1,346,174 | Exempt: 0 | TRF Vol: 2,208,593 | Short Ratio: 61.0% | Off-exchange volume (dark pool + OTC)
Jul 22, 2026
other
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of BioLife Solutions, Inc. (NASDAQ: BLFS)
NEW YORK, July 22, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recov
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.07 | $0.07–$0.07 | 66.9% | +0.0% | — | $0.0B | 1 |
| Next Q | $0.08 | $0.08–$0.08 | 105.1% | +0.0% | — | $0.0B | 1 |
| Current FY | $0.25 | $0.25–$0.25 | 91.9% | +0.0% | 0↑ 1↓ | $0.1B | 1 |
| Next FY | $0.33 | $0.33–$0.33 | 32.0% | +13.8% | 1↑ 0↓ | $0.1B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.070 | — |
| 7d ago | $0.070 | — |
| 30d ago | $0.070 | — |
| 60d ago | $0.070 | — |
| 90d ago | $0.040 | +0.030 |
Institutional ownership
Which big funds own BLFS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $828.8M total value (29,349,000 shares) as of 2026-Q2. Top holders: BlackRock,, Invesco, VANGUARD. Net buying activity: 14 institutions added/increased vs 10 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 6,375,545 | $180.0M | 21.7% | — |
| Invesco Ltd. | 2,240,423 | $63.3M | 7.6% | TRIM -40.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,964,084 | $55.5M | 6.7% | — |
| STATE STREET CORP | 1,655,927 | $46.8M | 5.6% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 1,086,865 | $30.7M | 3.7% | — |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 1,079,270 | $30.5M | 3.7% | — |
| FRED ALGER MANAGEMENT, LLC | 1,077,577 | $30.4M | 3.7% | — |
| DIMENSIONAL FUND ADVISORS LP | 1,046,252 | $29.5M | 3.6% | — |
| FMR LLC | 993,106 | $28.0M | 3.4% | TRIM -32.5% |
| BANK OF AMERICA CORP /DE/ | 950,159 | $26.8M | 3.2% | ADD +73.4% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| FMR LLC | TRIM | 1,470,252 | 993,106 | -32.5% | $28.0M |
| UBS Group AG | DOUBLED | 265,978 | 832,143 | +212.9% | $23.5M |
| MILLENNIUM MANAGEMENT LLC | NEW | — | 625,658 | — | $17.7M |
| GOLDMAN SACHS GROUP INC | DOUBLED | 265,487 | 531,582 | +100.2% | $15.0M |
| Rockefeller Capital Management L.P. | TRIM | 741,352 | 445,020 | -40.0% | $12.6M |
| ENVESTNET ASSET MANAGEMENT INC | TRIM | 242,439 | 161,457 | -33.4% | $4.6M |
| CITADEL ADVISORS LLC | TRIM | 244,172 | 157,944 | -35.3% | $4.5M |
| Man Group plc | DOUBLED | 72,626 | 145,503 | +100.3% | $4.1M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | DOUBLED | 14,684 | 142,680 | +871.7% | $4.0M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | 89,100 | 132,891 | +49.1% | $3.8M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 50 transactions. Net -$30.2M — $0.00 bought, $30.2M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | Berard Todd | Chief Marketing Officer | TAX W/H | 470 | $36.69 | $17.2K |
| Sep 18, 2026 | Werner Sean | Chief Technology Officer | TAX W/H | 421 | $36.69 | $15.4K |
| Sep 18, 2026 | Mathew Aby J. | EVP & Chief Scientific Officer | TAX W/H | 564 | $36.69 | $20.7K |
| Sep 18, 2026 | DE GREEF RODERICK | President and CEO | TAX W/H | 2,775 | $36.69 | $101.8K |
| Sep 18, 2026 | Wichterman Troy | Chief Financial Officer | TAX W/H | 937 | $36.69 | $34.4K |
| Sep 8, 2026 | Berard Todd | Chief Marketing Officer | TAX W/H | 356 | $35.38 | $12.6K |
| Sep 8, 2026 | Wichterman Troy | Chief Financial Officer | TAX W/H | 1,026 | $35.38 | $36.3K |
| Sep 8, 2026 | Mathew Aby J. | EVP & Chief Scientific Officer | TAX W/H | 627 | $35.38 | $22.2K |
| Jul 17, 2026 | Werner Sean | Chief Technology Officer | TAX W/H | 275 | $29.15 | $8.0K |
| Jul 7, 2026 | Berard Todd | Chief Marketing Officer | TAX W/H | 293 | $27.79 | $8.1K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for BLFS.
Shares short
3,884,193
Settlement Sep 15, 2026
Change vs prior
-1.1%
Semi-monthly cycle
Days to cover
4.5
At avg daily volume
Of shares outstanding
≈7.9%
Estimate — not % of float
All BLFS filing & press-release reports (5)
- DEFM14A reportSep 4, 2026
- 8-K reportJun 3, 2026
- 10-K/A reportApr 28, 2026
- CLUSTER reportMar 9, 2026
- CLUSTER reportMar 5, 2026